GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (NAS:TMDX) » Definitions » Price-to-Owner-Earnings

TransMedics Group (TransMedics Group) Price-to-Owner-Earnings : (As of May. 15, 2024)


View and export this data going back to 2019. Start your Free Trial

What is TransMedics Group Price-to-Owner-Earnings?

As of today (2024-05-15), TransMedics Group's share price is $135.48. TransMedics Group does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for TransMedics Group's Price-to-Owner-Earnings or its related term are showing as below:


TMDX's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.93
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-15), TransMedics Group's share price is $135.48. TransMedics Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.34. Therefore, TransMedics Group's PE Ratio for today is At Loss.

As of today (2024-05-15), TransMedics Group's share price is $135.48. TransMedics Group's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.34. Therefore, TransMedics Group's PE Ratio without NRI for today is At Loss.


TransMedics Group Price-to-Owner-Earnings Historical Data

The historical data trend for TransMedics Group's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group Price-to-Owner-Earnings Chart

TransMedics Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

TransMedics Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of TransMedics Group's Price-to-Owner-Earnings

For the Medical Devices subindustry, TransMedics Group's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TransMedics Group's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where TransMedics Group's Price-to-Owner-Earnings falls into.



TransMedics Group Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

TransMedics Group's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=135.48/-2.88
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TransMedics Group  (NAS:TMDX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


TransMedics Group Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of TransMedics Group's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


TransMedics Group (TransMedics Group) Business Description

Traded in Other Exchanges
Address
200 Minuteman Road, Andover, MA, USA, 01810
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.
Executives
Tamer I Khayal officer: Chief Commercial Officer TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
Miriam Provost officer: VP of US Regulatory & FDA Rel. 2000 MINUTEMAN ROAD, ANDOVER MA 01810
Waleed H Hassanein director, officer: President & CEO TRANSMEDICS INC, 200 MINUTEMAN ROAD, ANDOVER MA 01810
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Stephen Gordon officer: Chief Financial Officer 200 MINUTEMAN ROAD, ANDOVER MA 01810
David Weill director 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Anil P. Ranganath officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Edward M Basile director 200 MINUTEMAN ROAD, ANDOVER MA 01810
John F Carey officer: VP of Operations 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Nicholas Corcoran officer: See Remarks C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Laura Damme officer: VP, Clinical Affairs C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
Stephanie Lovell director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Kania Edwin M Jr director
Rakesh P. Godhani officer: Chief Digital Officer C/O TRANSMEDICS GROUP, INC., 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810
John F Sullivan officer: VP of Quality & Engineering 200 MINUTEMAN ROAD, SUITE 302, ANDOVER MA 01810